This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
by Kanishka Das
Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
SNYNegative Net Change TEVAPositive Net Change FOLDPositive Net Change
biotechs
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
by Zacks Equity Research
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
BMYPositive Net Change BAYRYPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
by Ahan Chakraborty
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
ALNYPositive Net Change NVSPositive Net Change PFEPositive Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
Is IPF the Next Big Market Opportunity for United Therapeutics?
by Sundeep Ganoria
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
UTHRNegative Net Change INSMNegative Net Change LQDAPositive Net Change
biotechs medical
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
by Zacks Equity Research
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
SNYNegative Net Change GILDPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
by Ahan Chakraborty
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?
by Zacks Equity Research
KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.
BMYPositive Net Change MRKNegative Net Change ABEONegative Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
by Kanishka Das
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.
JAZZPositive Net Change ACADNegative Net Change AXSMPositive Net Change
biotechs
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
by Sundeep Ganoria
ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.
RDYNegative Net Change TEVAPositive Net Change ALVONegative Net Change
biotechs medical
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
by Zacks Equity Research
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
HALOPositive Net Change ABBVNegative Net Change ANIPNegative Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
by Zacks Equity Research
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change RARENegative Net Change
biotechnology biotechs medical pharmaceuticals
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
by Sundeep Ganoria
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
JNJNegative Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program
by Zacks Equity Research
Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.
CRMDNegative Net Change CDTXPositive Net Change KNSANegative Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
by Ekta Bagri
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
BMYPositive Net Change MRKNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
by Ekta Bagri
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
AZNPositive Net Change JNJNegative Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
by Kanishka Das
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
SNYNegative Net Change RIGLNegative Net Change FOLDPositive Net Change
biotechs medical
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
by Zacks Equity Research
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.
AZNPositive Net Change RHHBYNegative Net Change PFEPositive Net Change MRKNegative Net Change
biotechs medical pharmaceuticals
QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study
by Zacks Equity Research
uniQure N.V. shares surge nearly 248% after its gene therapy candidate, AMT-130, met key goals in a pivotal Huntington's disease study.
CRMDNegative Net Change QURENegative Net Change KNSANegative Net Change PHARNegative Net Change
biotechnology biotechs gene-therapy genomics medical pharmaceuticals
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
by Zacks Equity Research
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
CRMDNegative Net Change ACADNegative Net Change SLNONegative Net Change KNSANegative Net Change
biotechnology biotechs medical pharmaceuticals
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
by Zacks Equity Research
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
HALOPositive Net Change ANIPNegative Net Change HRMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
by Sundeep Ganoria
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
by Zacks Equity Research
FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.
NVSPositive Net Change BIIBPositive Net Change RHHBYNegative Net Change IONSPositive Net Change
biotechs
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug
by Zacks Equity Research
Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.
BMYPositive Net Change CRMDNegative Net Change REPLNegative Net Change KNSANegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
by Zacks Equity Research
Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.
GSKNegative Net Change MRKNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
by Zacks Equity Research
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
BMYPositive Net Change HALOPositive Net Change ANIPNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals